Optimizing Salmonella enterica serovar Typhimurium for bacteria-mediated tumor therapy. (3rd March 2016)

• Record Type: Journal Article
• Authors: Felgner, Sebastian; Kocijancic, Dino; Frahm, Michael; Curtiss, Roy; Erhardt, Marc; Weiss, Siegfried
• Is Part Of: Gut microbes. Volume 7:Isuse 2(2016)
• Page Start: 171
• Page End: 177
• Publication Date: 2016-03-03
• Subjects: bacteria-mediated tumor therapy -- LPS -- Lipid A -- Salmonella Typhimurium -- UK-1; Gastrointestinal system -- Microbiology -- Periodicals; Microbiology -- Periodicals; Intestine, Small -- Periodicals; 616.3
• DOI: 10.1080/19490976.2016.1155021
• Languages: English
• ISSNs: 1949-0984

Abstract

ABSTARCT: Bacteria-mediated tumor therapy using Salmonella enterica serovar Typhimurium is a therapeutic option with great potential. Numerous studies explored the potential of Salmonella Typhimurium for therapeutic applications, however reconciling safety with vectorial efficacy remains a major issue. Recently we have described a conditionally attenuated Salmonella vector that is based on genetic lipopolysaccharide modification. This vector combines strong attenuation with appropriate anti-tumor properties by targeting various cancerous tissues in vivo . Therefore, it was promoted as an anti-tumor agent. In this addendum, we summarize these findings and demonstrate additional optimization steps that may further improve the therapeutic efficacy of our vector strain.